The team behind the work set out to answer a deceptively simple question: what actually breaks inside brain cells when sleep is withheld, and can the damage be reversed? Previous studies had established that sleep deprivation disrupts glucose metabolism, damages mitochondria and triggers neuroinflammation, but the molecular pathway connecting these phenomena remained murky. APPL1 was a compelling candidate because it regulates insulin sensitivity and exerts anti-inflammatory effects in peripheral tissues, yet almost nothing was known about what it does in the brain under conditions of sleep deprivation.

To find out, the researchers subjected C57BL/6 mice to seven days of sleep deprivation and then used adeno-associated viral vectors to overexpress APPL1 specifically in hippocampal neurons. This is a crucial detail of the experimental design: rather than altering the protein throughout the body, the team targeted the brain region most closely associated with memory and learning. They then assessed mitochondrial dynamics, glucose metabolism, neural morphology and cognitive function using a battery of techniques including immunofluorescence, electron microscopy, western blotting, Golgi staining and behavioral testing.

The picture that emerged from the sleep-deprived mice was grim. The animals showed significant impairments in glucose metabolism and marked disruptions in mitochondrial morphology, along with substantial weight loss and elevated levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-6 and interleukin-1 beta, in the hippocampus. Equally telling was what had disappeared: the expression of key mitochondrial regulators, among them APPL1 itself, Rab32, phosphorylated DRP1 at the Ser637 residue, and cytochrome c oxidase subunit IV, or COX4, was notably diminished. In other words, sleep loss did not merely damage mitochondria; it appeared to strip away the very proteins that keep them healthy.

Mitochondria are not static organelles. They constantly fuse, divide and redistribute themselves in response to cellular demands, a process known as mitochondrial dynamics. When that balance collapses, energy production falters, reactive oxygen species accumulate and neurons begin to fail. The downregulation of p-DRP1, a phosphorylated form of dynamin-related protein 1 that helps govern mitochondrial fission, and COX4, a core component of the electron transport chain, suggested that sleep-deprived neurons were losing both the architectural control and the metabolic machinery of their power supplies.

To dissect the mechanism at the cellular level, the researchers turned to primary neurons exposed to lipopolysaccharide, an inflammatory stimulus that mimics some of the molecular stress of sleep deprivation. When APPL1 was activated in these neurons, it promoted its own colocalization with Rab32, a protein previously implicated in mitochondrial dynamics, and set off a cascade of restorative effects. Levels of p-DRP1 and COX4 rose, malondialdehyde, a marker of lipid peroxidation and oxidative damage, fell, and the activities of the antioxidant enzymes superoxide dismutase and glutathione peroxidase increased. Together, these changes restored mitochondrial function, morphology and network integrity. The clincher came when the team knocked down Rab32: every one of APPL1’s beneficial effects vanished, demonstrating that Rab32 is not merely a bystander but an essential mediator of the pathway.

Two independent techniques confirmed the physical relationship between the proteins. Co-immunoprecipitation showed that APPL1 and Rab32 associate with each other inside cells, while molecular docking studies predicted a structurally plausible binding interface between the two molecules. This convergence of biochemical and computational evidence strengthens the case that APPL1 acts directly through Rab32 rather than through some parallel route, and it places the APPL1-Rab32-p-DRP1 axis at the heart of mitochondrial maintenance in stressed neurons.

The in vivo results were equally striking. When APPL1 was overexpressed in the hippocampal neurons of sleep-deprived mice, Rab32 expression in the hippocampus improved, mitochondrial and neuronal morphology were restored, neuroinflammation subsided and cognitive deficits eased. Behavioral tests, including the novel object recognition test, reflected genuine functional recovery rather than mere biochemical correction. The authors also explored a translational angle: they engineered a recombinant fusion protein, TAT-APN, which combines the cell-penetrating TAT peptide, derived from the transactivator of transcription protein, with the N-terminal region of APPL1. The TAT tag is famous for its ability to cross the blood-brain barrier, and the team’s analyses suggest that TAT-APN can serve as a therapeutic agent to improve cognitive function in sleep-deprived mice, offering a potential route toward protein-based treatment.

What makes the study conceptually important is the bridge it builds between two usually separate research worlds: mitochondrial dysfunction and insulin resistance. APPL1 sits at the intersection of both. In peripheral tissues it enhances insulin signaling, and in the brain it now appears to protect mitochondria through Rab32. The authors argue that their findings emphasize the interplay between mitochondrial dysfunction and insulin resistance in the brain in the context of cognitive impairment, a framing that resonates with growing interest in the metabolic roots of neurological disease. Conditions ranging from Alzheimer’s disease to shift-work-related cognitive decline involve both metabolic dysregulation and mitochondrial failure, and a pathway that connects them offers a unified target.

There are, of course, the usual caveats that separate mouse studies from human medicine. Seven days of enforced sleep deprivation in a laboratory mouse is an extreme model, and the therapeutic candidate, TAT-APN, has so far been evaluated only in animals, with purification support from a commercial partner in Wuhan. The work was funded by the National Natural Science Foundation of China, the Liaoning Provincial Natural Science Foundation and a Dalian municipal health program, reflecting a sustained institutional bet on sleep and metabolism research. Still, the study delivers something rare in the field: a complete mechanistic arc, from a behavioral symptom to a molecular interaction to a candidate drug, all documented within a single paper. If the APPL1-Rab32 pathway holds up in further studies, the prospect of a molecule that can slip through the blood-brain barrier and reboot the brain’s mitochondrial dynamics after sleep loss would transform how we think about the cost of a sleepless week, and how we might pay it back.

Subject of Research: How the protein APPL1 regulates mitochondrial dynamics via Rab32 to alleviate cognitive deficits caused by sleep deprivation in mice

Article Title: APPL1, a novel protein, alleviates cognitive deficits via Rab32-mediated mitochondrial dynamics in a mouse model of sleep deprivation

Article References: Li, L., Mou, Y., Gao, X., Zhai, Y., Zhang, X., Wang, Q., & Xiao, Z. (2026). APPL1, a novel protein, alleviates cognitive deficits via Rab32-mediated mitochondrial dynamics in a mouse model of sleep deprivation. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08975-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08975-5

Keywords: sleep deprivation, APPL1, Rab32, mitochondrial dynamics, cognitive function, hippocampus, neuroinflammation, brain insulin resistance, p-DRP1, TAT-APN, oxidative stress, C57BL/6 mice

The finding addresses one of oncology’s most persistent complications. Doxorubicin belongs to the anthracycline class of chemotherapy drugs and is used against a wide range of blood cancers and solid tumors. Its anticancer activity is linked to several mechanisms, including interference with topoisomerase II, an enzyme that manages DNA structure, and the generation of reactive oxygen species. These effects can be highly effective against rapidly dividing cancer cells, but cardiac tissue is especially vulnerable because heart muscle cells depend heavily on mitochondria to produce the energy required for continuous contraction. Unlike many other tissues, the adult heart has limited capacity to replace injured cardiomyocytes.

Mitochondria are not static structures. They constantly divide and fuse in a process known as mitochondrial dynamics, allowing cells to distribute energy-producing components, remove damaged regions and adapt to changing metabolic demands. Drp1 is a central molecular engine of mitochondrial fission. When activated, it moves from the cytosol to the mitochondrial surface, where it assembles around the organelle and constricts the membrane until one mitochondrion separates into two. Controlled fission is essential for healthy cells, but excessive or poorly regulated Drp1 activity can produce a fragmented mitochondrial network that is less efficient and more vulnerable to further damage.

The new study places this abnormal fission response at the center of doxorubicin-induced cardiotoxicity. According to the researchers, exposure to the chemotherapy drug promoted Drp1-dependent mitochondrial disruption in cardiac cells. Excessive fragmentation can impair the electron transport chain, the series of protein complexes that generates most cellular ATP through oxidative phosphorylation. At the same time, damaged mitochondria may leak more electrons, increasing the formation of reactive oxygen species. These chemically reactive molecules can attack membrane lipids, proteins and DNA, creating a self-reinforcing cycle of oxidative stress, mitochondrial failure and cell injury.

DRP1i2 was investigated as a pharmacological means of interrupting that cycle. By inhibiting Drp1 activity, the compound is designed to restrain excessive mitochondrial division without eliminating mitochondrial dynamics altogether. That distinction matters. Completely freezing fission would also interfere with normal mitochondrial quality control, including the segregation of damaged mitochondrial material for removal through mitophagy. A useful inhibitor would therefore need to reduce pathological fragmentation while preserving enough dynamic behavior for cardiac cells to maintain their organelles.

The researchers assessed whether DRP1i2 could preserve several features of cardiac-cell health after doxorubicin treatment. These types of experiments typically include measurements of mitochondrial morphology, membrane potential, oxygen consumption, cellular ATP production and the accumulation of reactive oxygen species, as well as indicators of apoptosis. The study’s central result was that DRP1i2 countered the damaging effects associated with doxorubicin, supporting the conclusion that excessive Drp1 activity is not merely a bystander effect but a therapeutically relevant part of the cardiotoxic process.

At the cellular level, protecting mitochondria may prevent the loss of cardiomyocytes before it becomes irreversible. A failing mitochondrial membrane potential limits ATP synthesis and can promote the opening of permeability pathways that trigger programmed cell death. Once apoptosis is activated, cardiomyocytes can be lost through a process involving mitochondrial release of pro-death factors, caspase activation and fragmentation of cellular DNA. By stabilizing mitochondrial function, Drp1 inhibition could reduce the biochemical signals that push stressed heart cells toward apoptosis. This mechanism is particularly important because cumulative injury may remain clinically silent for years before emerging as reduced cardiac contractility.

The work also highlights why cardiotoxicity is difficult to solve with a single antioxidant. Reactive oxygen species are part of the damage caused by doxorubicin, but they are also products of broader mitochondrial and metabolic disturbances. Simply neutralizing oxidants may not correct the structural defects that allow dysfunctional mitochondria to accumulate. Targeting Drp1 addresses an upstream process: the physical remodeling of mitochondria that can intensify oxidative stress, disrupt energy production and activate cell-death pathways. The approach therefore represents a shift from treating one chemical consequence of doxorubicin exposure to modifying the organelle-level response that helps generate several consequences at once.

The findings remain a preclinical advance rather than a ready-to-use treatment for patients receiving chemotherapy. A cardioprotective drug would need to shield the heart without weakening doxorubicin’s ability to kill tumor cells. That question is central to future studies, because mitochondrial fission and Drp1 signaling can also influence the survival, metabolism and stress responses of cancer cells. Researchers will need to determine the appropriate dose and timing of DRP1i2, establish how long its protective effects last, and test whether it interacts with doxorubicin’s anticancer activity in different tumor types. Animal studies and, eventually, carefully designed clinical trials will also be required to examine pharmacokinetics, toxicity and effects on heart function over both short and long periods.

Even with those questions unresolved, the study offers a compelling molecular explanation for how a widely used chemotherapy can injure the heart and identifies Drp1 inhibition as a possible countermeasure. The broader significance extends beyond doxorubicin: excessive mitochondrial fission has been implicated in ischemia-reperfusion injury, neurodegeneration, metabolic disease and other disorders in which cellular energy systems collapse under stress. DRP1i2 may therefore serve not only as a candidate cardioprotective compound but also as a tool for testing how mitochondrial architecture governs disease. For cancer medicine, the immediate promise is clear—protecting the heart could allow patients to receive life-saving anthracycline therapy with fewer long-term cardiac consequences, provided future research confirms that mitochondrial protection can be achieved without compromising cancer treatment.

Subject of Research: Cardioprotection against doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated mitochondrial fission

Article Title: The Drp1 inhibitor DRP1i2 confers cardioprotection against doxorubicin-induced cardiotoxicity

Article References: Deng, Y., Bass-Stringer, S.T., Bond, S.T. et al. “The Drp1 inhibitor DRP1i2 confers cardioprotection against doxorubicin-induced cardiotoxicity.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03311-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03311-8

Keywords: Doxorubicin, cardiotoxicity, Drp1, DRP1i2, mitochondrial fission, mitochondrial dynamics, cardioprotection, oxidative stress, apoptosis, cancer therapy